We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


CombiMatrix Molecular Diagnostics Launches Next Version of its Constitutional Genetic Array Test

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CombiMatrix Molecular Diagnostics Launches Next Version of its Constitutional Genetic Array Test"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Acacia Research Corporation announced has that its CombiMatrix group’s subsidiary, Combimatrix Molecular Diagnostics (CMDX), has completed the clinical validation of and has launched the third version of its Constitutional Array Genetic Test (CA1000).

The test utilizes the company’s Bacterial Artificial Chromosome (BAC) array, which includes over 200 new, validated probes obtained through the company’s partnerships with The Center of Applied Genomics (TCAG), in Toronto, Canada and the Erasmus University Medical Center, the Netherlands’ largest academic medical center.

According to Company, the CA1000 improves upon the previous CA850 by virtue of its increased coverage of genomic loci found in disease hotspots further enhancing the test’s ability to detect and characterize common genetic disorders. Moreover, greater background genomic coverage has been added to the CA1000 enabling the broader detection of spurious chromosomal abnormalities.

The CA1000 array now has the robust, clinically validated genomic coverage in the industry. The demonstrated serial development of CMDX’s arrays, enabled by platform flexibility and partnerships with academic centers, underscores the ability to incorporate the latest genetic information available at a pace.

“As clinical diagnostics continue to take advantage of the rapidly increasing knowledge of the molecular basis for diseases, cutting-edge test development must be able to incorporate new information as efficiently as possible. In few other diagnostics specialties is this more evident, however challenging, than in genomics testing,” said Dr. Mercedes Gorre, VP of Scientific Affairs at CMDX.

“From the outset, it has been clear to us that this emergent field of clinical diagnostics will require the ability to respond to the evolving body of knowledge of genetic disease associations and so we developed a system of platform flexibility, content procurement, and clinical validation that could accommodate such standards. An added advantage is that this also allows us to seamlessly integrate client suggested content into our development pipeline further enabling the most clinically relevant tests in the market.”

“Combimatrix Molecular Diagnostics has delivered excellent results for us with their 'CA 850' microarray. We are particularly pleased with CMDX’s continued advancement of their microarray products and services, and eagerly anticipate utilizing the new 'CA 1000' with enhanced genomic coverage. Their state-of-the-art microarray products and services deliver cutting edge technologies to our patients,” said Dr. Dianne Abuelo, M.D., Director of the Genetics Division, Department of Pediatrics, Hasbro Children's Hospital, Providence, Rhode Island.